Loading clinical trials...
Loading clinical trials...
A Phase II Study of Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer
Conditions
Interventions
H101
Tislelizumab
+1 more
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Start Date
May 16, 2023
Primary Completion Date
December 30, 2025
Completion Date
December 30, 2025
Last Updated
June 27, 2023
NCT06708858
NCT04172402
NCT05009953
NCT04217954
NCT04211168
NCT03358849
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions